Skip to main content
. 2020 Jun 19;11:937. doi: 10.3389/fphar.2020.00937

Figure 5.

Figure 5

Current 2020 and projected timelines (shown in four quarters, Q1–Q4) for 14 vaccine candidates, grouped by platform, either funded by (CEPI/BARDA, and currently in (or approaching) clinical development for COVID-19. The two candidates using viral vector (replicating) from Pasteur/Themis (Merck) and live attenuated virus (Univ Hong Kong) funded by CEPI, covered in the main text body, are not included here because they are still too early in development and without sufficient information. M, million; B, billion; Ph, Phase. Sources include publicly available company websites.